Aindra Systems

CervAstraSolution

SHARE

One woman dies every 2 minutes globally due to Cervical Cancer. Currently, there exists no reliable, smart and fast solution for the screening of Cervical Cancer in all developing nations. Although cervical cancer has a higher gestation period, due to lack of affordable and accessible screening tests, the count of women detected with Cervical Cancer is rising and so is the mortality.

Most popular related searches

CervAstra, our first product to detect Cervical Cancer is built using ASTRA, our Computational Pathology platform. CervAstra analyzes pap smear samples at the Point-of-Care to call out Normal or Abnormal all in under a few hours as opposed to a larger turnaround time of a few weeks depending on the location of sample collection.